认知疗法治疗多重创伤后儿童青少年PTSD的实用性随机对照试验:DECRYPT试验
该实用性随机对照试验纳入120名暴露于多重创伤的8-17岁PTSD患者,随机接受CT-PTSD或常规治疗。治疗后CRIES-8评分组间差异未达显著,但11个月随访时CT-PTSD显著优于常规治疗,且耐受性良好。
要点
- CT-PTSD在治疗后未显著优于常规治疗,但11个月随访时显著改善PTSD症状。
- 排除接受过TF-CBT的常规治疗患者后,CT-PTSD在治疗后即显示显著优势。
- 基线复杂PTSD诊断常见(55.0%),共病率高,但CT-PTSD未导致显著恶化或不良事件。
核心结论
- CT-PTSD在多重创伤后PTSD儿童青少年中未能在治疗后立即显著优于常规治疗,但在11个月随访时显示显著优势,且耐受性良好。
研究设计与样本
- 实用性随机对照试验纳入120名8-17岁暴露于多重创伤且符合PTSD诊断的青少年,随机分配至CT-PTSD组或常规治疗组。
- 基线时复杂PTSD诊断占55.0%,共病精神障碍比例高。
- 主要结局为治疗后儿童修订版事件影响量表8条目版(CRIES-8)评分。
主要发现
- 治疗后CRIES-8评分组间调整差异为-3.80(95%CI:-7.56至-0.06,p=0.095;Hedges' g=-0.37,95%CI:-0.78至0.03),未达显著。
- 排除常规治疗组中接受过TF-CBT的患者后,CT-PTSD组CRIES-8评分显著优于常规治疗(调整差异-4.60,95%CI:-8.36至-0.81,p=0.047;g=-0.46,95%CI:-0.89至-0.04)。
- 11个月随访时CT-PTSD组CRIES-8评分显著优于常规治疗(调整差异-5.38,95%CI:-8.88至-1.87,p=0.003;g=-0.46,95%CI:-0.90至-0.02)。
- 混合效应模型纳入所有时间点显示CT-PTSD优于常规治疗(p=0.007)。
- CT-PTSD在治疗后和11个月家长报告的情绪困难、11个月儿童报告的焦虑抑郁总分、焦虑总分、惊恐和分离焦虑、家长报告的情感调节障碍和易激惹方面显示优势。
关键数值与推荐
- 主要结局CRIES-8治疗后调整差异-3.80(95%CI:-7.56至-0.06,p=0.095;Hedges' g=-0.37,95%CI:-0.78至0.03)。
- 排除TF-CBT暴露后CRIES-8调整差异-4.60(95%CI:-8.36至-0.81,p=0.047;g=-0.46,95%CI:-0.89至-0.04)。
- 11个月CRIES-8调整差异-5.38(95%CI:-8.88至-1.87,p=0.003;g=-0.46,95%CI:-0.90至-0.02)。
- 混合效应模型所有时间点p=0.007。
- 治疗脱落率低,未观察到显著恶化或不良事件。
临床怎么用
- 对于多重创伤后PTSD且共病严重的儿童青少年,CT-PTSD可作为常规治疗外的选择,尤其关注长期随访中的获益。
- 需注意常规治疗中部分患者可能已接受TF-CBT,可能稀释组间差异。
- CT-PTSD耐受性良好,未增加不良事件风险。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Trauma-focused cognitive-behavioral therapies (TF-CBTs) are efficacious in children and adolescents with post-traumatic stress disorder (PTSD). However, there is limited evidence in youth exposed to multiple traumas, especially in real-world settings. This paper reports on a pragmatic randomized controlled trial (RCT) evaluating whether one form of TF-CBT, cognitive therapy for PTSD (CT-PTSD), was effective for PTSD following multiple trauma exposure in 8-17 year-olds attending UK mental health services, relative to treatment-as-usual (TAU). Youth with PTSD (N=120) following multiple traumas were randomly allocated to receive CT-PTSD or TAU. At baseline, complex PTSD diagnosis was common (55.0% of cases), and a large proportion of youth had comorbid mental disorders. The primary outcome was the score on the Child Revised Impact of Event Scale, 8-item version (CRIES-8) at post-treatment. Secondary outcomes included the CRIES-8 score at 11 months post-randomization, and several measures of PTSD, anxiety, depression, suicidal ideation, affect regulation, irritability, and general functioning at post-treatment and 11 months post-randomization. CT-PTSD was not found to be significantly superior to TAU on the CRIES-8 at post-treatment (adjusted difference: -3.80, 95% CI: -7.56 to -0.06, p=0.095; Hedges' g=-0.37, 95% CI: -0.78 to 0.03), but it was superior to TAU when patients who had received TF-CBT were excluded from that arm (adjusted difference: -4.60, 95% CI: -8.36 to -0.81, p=0.047; g=-0.46, 95% CI: -0.89 to -0.04). CT-PTSD was also superior to TAU on the CRIES-8 at 11 months (adjusted difference: -5.38, 95% CI: -8.88 to -1.87, p=0.003; g=-0.46, 95% CI: -0.90 to -0.02), and in a mixed-effect model incorporating all time points (p=0.007). Evidence of superiority for CT-PTSD was observed on parent-reported emotional difficulties at post-treatment and 11 months; and on child-reported total anxiety and depression, total anxiety, panic and separation anxiety, and parent-reported affect dysregulation and irritability at 11 months. Treatment withdrawal rate was low. Despite high baseline levels of comorbidity and impairment not seen in previous trials, CT-PTSD was not associated with significant deterioration or adverse events. This pragmatic trial is likely to contribute to the optimization of psychological intervention in youth with PTSD following multiple traumas, accompanied by severe comorbid mental disorders, in routine settings.
引用
- Meiser-Stedman R, Allen L, Ashford PA, et al. A pragmatic randomized controlled trial of cognitive therapy for post-traumatic stress disorder in children and adolescents exposed to multiple traumatic stressors: the DECRYPT trial. World Psychiatry. 2025. PMID: 40948050. doi:10.1002/wps.21355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。